WATERTOWN, Mass.--(BUSINESS WIRE)--
Tetraphase Pharmaceuticals, Inc. (TTPH) today announced that it will present at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) the results of important research that supports the potential of the company’s next-generation antibiotics portfolio, including its lead candidate eravacycline in the treatment of difficult-to-treat bacterial infections (e.g., serious Gram-negative and biothreat infections). Data to be presented will highlight dosing of eravacycline in the company’s Phase 2 clinical trial in complicated intra-abdominal infections (cIAI) as well as its activity in preclinical studies against neisseria gonorrhoeae, a common but increasingly resistant cause of gonococcal disease. Tetraphase recently dosed the first patient in its Phase 3 clinical trial in cIAI. This marks the first of two planned Phase 3 clinical trials: one in complicated intra-abdominal infections and one in complicated urinary tract infections (which the company plans to initiate later this year).
ICAAC will occur September 10 to 13, 2013, in Denver, CO. An additional preclinical study to be presented at ICAAC examines the company’s unique synthetic tetracycline platform, and its ability to combat serious Gram-negative infections, including those caused by Pseudomonas aeruginosa. Data will also be shared on preclinical antibiotic candidate TP-271’s ability to combat the effects of aerosolized biological weapons, specifically the highly virulent pathogen francisella tularensis.
“ICAAC occurs at an exciting time for us this year, as we begin our Phase 3 program for eravacycline,” said Guy Macdonald, Tetraphase President and Chief Executive Officer. “Our research shared at ICAAC highlights the overall depth and breadth of our antibiotics portfolio. With our ability to manipulate the tetracycline molecule, Tetraphase researchers are developing multiple novel antibiotics with the potential to address significant public health concerns arising from multi-drug resistant infections caused by a range of pathogens, including those in the Gram-negative space and those that may be caused by biothreat pathogens.”
Details of the sessions related to lead candidate eravacycline at ICAAC include:
- “Pharmacokinetic-Pharmacodynamic (PK-PD) and Dose Selection Analyses for Eravacycline Using Phase 2 Data from Patients with Community-Acquired Complicated Intra-Abdominal Infections (cIAI).” [A-293] Tuesday, September 10, 2013, 5:15 – 5:30 p.m. Slide Session 034, Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: (Meeting Room 405)
- “Eravacycline (TP-434) is active against susceptible and multidrug-resistant Neisseria gonorrhoeae.” [E-1181] Thursday, September 12, 2013, 11:00 a.m. – 1:00 p.m. Poster Session 153, New Agents, Formulations and Repurposing of Licensed Drugs: (Exhibit Hall A)
- “Plasma Protein Binding of Eravacycline in Mouse, Rat, Rabbit, Cynomolgus Monkey, African Green Monkey and Human Using Microdialysis.” [A-015] Tuesday, September 10, 2013, 12:00 – 2:00 p.m. Poster Session 004, Pharmacokinetics/ Pharmacodynamics of New Anti-Infective Agents: (Exhibit Hall A)
- “Comparative Analysis of Eravacycline by Broth Microdilution and Disk Diffusion.” [E-1180] Thursday, September 12, 2013, 11:00 a.m. – 1:00 p.m. Poster Session 153, New Agents, Formulations and Repurposing of Licensed Drugs: (Exhibit Hall A)
Additional posters at ICAAC supporting Tetraphase’s proprietary chemistry platform and preclinical program include:
- “Novel 7-Trifluoromethyl-8-Heterocyclyl Tetracyclines with Promising Antibacterial Activity against Gram-positive and Gram-negative Pathogens, including Pseudomonas aeruginosa.” [F-632] Wednesday, September 11, 2013, 11:00 a.m. – 1:00 p.m. Poster Session 83, Inhibition of Bacterial Protein Synthesis: (Exhibit Hall A)
- “TP-271, a novel fluorocycline, is efficacious in a post-exposure prophylaxis (PEP) model of aerosolized Francisella tularensis infection in BALB/c mice.” [F-633] Wednesday, September 11, 2013, 11:00 a.m. – 1:00 p.m. Poster Session 83, Inhibition of Bacterial Protein Synthesis: (Exhibit Hall A)
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections. Tetraphase's lead product candidate, eravacycline, is a fully synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including MDR Gram-negative infections.
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether our cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in preclinical studies and early clinical trials, such as the results referred to in this press release, will be indicative of results obtained in future clinical trials; whether we are able to develop an oral formulation of eravacycline on a timely basis or at all; whether eravacycline will advance into clinical trials and through the clinical trial process on a timely basis and receive approval from the FDA or equivalent foreign regulatory agencies; whether, if eravacycline obtains approval, it will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of our quarterly report on Form 10-Q for the quarter ended June 30, 2013. The forward-looking statements included in this press release represent our views as of September 4, 2013. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.
- Health Care Industry
- Pharmaceuticals & Drug Trials
- clinical trial